Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

These trials, including those from companies like Eisai and UCB, have demonstrated robust target ... JMP Securities also reiterated a Buy rating on the stock with a $83.00 price target. TipRanks ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

BioArctic's Leqembi, the first FDA-approved Alzheimer's drug, faces EMA rejection but could see a stock surge with a positive ... drug as recent as last week. Eisai has already requested a ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on AVXL stock, giving a Buy rating on October 18. Soumit Roy has given his ...

AAII’s A+ Investor Value Grade is derived from a stock’s value score. The value score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

Eisai Co., Ltd.-12.26%-37.11% ...

Revolution Medicines, Inc. +25.20% +148.60% ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...